ConcertAI, a US-based company that deals with oncology predictive and generative AI SaaS Solutions and Real-World Data for healthcare and life sciences, announced on Monday that it has named Timothy (Tim) Albury as its new chief financial officer (CFO).
Albury, an accomplished finance executive, has served for 12 years at Arthur Andersen and around 25 years as CFO of various companies across multiple industry sectors. He has most recently served as CFO of AQuity Solutions. He was also a part of the leadership team growing KBI BioPharma, Osmotica Pharma, and Liquidia Corp (LQDA).
Albury said, 'ConcertAI is uniquely poised to expand its position as the clinical AI and Real-World Data leader. I am excited to join the talented ConcertAI team as the company enters a new phase of growth by bringing predictive and generative AI SaaS innovations to our customers in healthcare and clinical development.'
Oncoinvent reports positive 18-month Phase 1 data for Radspherin in ovarian cancer trial
Camurus' Oczyesa recommended for European regulatory approval for acromegaly treatment
Innovent's limertinib receives Chinese regulatory approval for first-line treatment of lung cancer
Johnson & Johnson reports TAR-200 monotherapy study data in bladder cancer
CHMP backs Camurus' Oczyesa for acromegaly treatment in EU
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Guardant Health and Pfizer enter global collaboration to advance cancer therapy development
Sanofi invests EUR15m in Innate Pharma to strengthen strategic partnership
Adcendo to present clinical stage ADC data at 2025 AACR Annual Meeting
Sebela Pharmaceuticals' tegoprazan Phase 3 TRIUMpH studies in GERD achieve positive topline results
BioArctic secures European substance patent for Parkinson's drug candidate exidavnemab
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older